In addition, the antibody also reduced the expression and release of Ang-2 in the ECs and inhibited infiltration of TEMs in CTHRC1-overexpressing tumor tissues, consistent with the inhibition of the proangiogenic programs of TEMs in murine tumors by Ang-2 blockade.38 Collectively, our findings suggest that the CTHRC1-neutralizing antibody has the potential to treat not only pancreatic cancer but also CTHRC1-overexpressing cancers, such as colon cancer, breast cancer and melanoma. This evidence concerns the gene CTHRC1 and familial pancreatic carcinoma.